Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Inclusion Criteria:

1. Voluntary participation and agree to all the purposes of the study by signing anddating ICF;

2. Male or female participantes, regardless of race or social class;

3. Participants aged ≥18 and ≤70 years;

4. Bearer dialysis-dependent CKD (hemodialysis and peritoneal dialysis *);

5. Clinical diagnosis of anemia, characterized as hemoglobin levels <10g/dL before thestart of the study;

6. Adequate dialysis: Kt / V ≥ 1.2 for hemodialysis patients (based on the calculation ofDaugirdas II) and ≥ 1.7 for patients on peritoneal dialysis;

7. Adequate iron stores (TSAT> 20% and serum ferritin> 100ng/ml) prior to initiation oftreatment with erythropoietin.

Exclusion Criteria:

1. Participation in clinical trials in the 12 months preceding the survey;

2. Patients with uncontrolled hypertension, with mean above 180/100mmHg and whoserequiring hospitalization in the last 6 months;

3. Presence of other causes of anemia than CKD, such as bleeding, hemolysis, perniciousanemia and hemoglobinopathies;

4. Patients who present changes or clinical abnormalities, qualified as interferingchanges, such as severe hyperparathyroidism (iPTH> 1000 pg / mL), severe congestiveheart failure (NYHA Class IV), acute myocardial infarction within the last 3 months,or active neoplasia in follow-up, severe liver disease, active infection (leukocytechanges), history of aluminum toxicity or scheduled surgery, pregnancy or lactation;

5. Patients who have a known hypersensitivity to any component of the formulation and toproducts derived from mammalian cells;

6. Prior therapies with erythropoietin for less than 3 months;

7. Realization transfusion for less than 3 months;

8. Any situation at the discretion of the Principal Investigator interfere with studydata.